ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.214,79
-0,51%
S&P 500
5.827,04
-1,54%
Dow Jones
41.938,45
-1,63%
Euro vs US Dollar
1,02545
0,00%
Bitcoin
95.135,01
0,60%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Allarity Therapeutics Inc (ALLR)

  7. Allarity Therapeutics Inc (ALLR) News

ALLR

Allarity Therapeutics (ALLR)

Allarity Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ALLR
DatumZeitQuelleÜberschriftSymbolFirma
19/11/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
18/11/202414h00GlobeNewswire Inc.Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate AdvancementsNASDAQ:ALLRAllarity Therapeutics Inc
14/11/202422h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLRAllarity Therapeutics Inc
14/11/202414h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
14/11/202414h00GlobeNewswire Inc.Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational HighlightsNASDAQ:ALLRAllarity Therapeutics Inc
23/10/202414h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
22/10/202414h00GlobeNewswire Inc.Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for StenoparibNASDAQ:ALLRAllarity Therapeutics Inc
11/10/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
10/10/202414h00GlobeNewswire Inc.Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementNASDAQ:ALLRAllarity Therapeutics Inc
04/10/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
03/10/202414h00GlobeNewswire Inc.Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor ProgramNASDAQ:ALLRAllarity Therapeutics Inc
01/10/202423h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLRAllarity Therapeutics Inc
01/10/202423h32Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALLRAllarity Therapeutics Inc
18/09/202422h05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALLRAllarity Therapeutics Inc
17/09/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
16/09/202414h00GlobeNewswire Inc.Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer TrialNASDAQ:ALLRAllarity Therapeutics Inc
13/09/202414h53Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
13/09/202414h45GlobeNewswire Inc.Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ALLRAllarity Therapeutics Inc
11/09/202414h00GlobeNewswire Inc.Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)NASDAQ:ALLRAllarity Therapeutics Inc
10/09/202415h15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ALLRAllarity Therapeutics Inc
09/09/202422h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLRAllarity Therapeutics Inc
09/09/202415h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
30/08/202422h05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALLRAllarity Therapeutics Inc
29/08/202423h57Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ALLRAllarity Therapeutics Inc
21/08/202422h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
05/08/202423h24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLRAllarity Therapeutics Inc
26/07/202415h00GlobeNewswire Inc.Allarity Therapeutics Announces Postponement of Annual Stockholders MeetingNASDAQ:ALLRAllarity Therapeutics Inc
26/07/202412h04Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ALLRAllarity Therapeutics Inc
24/07/202412h00GlobeNewswire Inc.Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized SharesNASDAQ:ALLRAllarity Therapeutics Inc
23/07/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALLR

Kürzlich von Ihnen besucht

LSE
59UR
Fed.rep.n. 49 A
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten